EUVIMEDEUVIMED entdecken
Crossref

A self-assembly nano-prodrug for triple-negative breast cancer combined treatment by ferroptosis therapy and chemotherapy

Yuan Chen, Zhuo Yao, Peilian Liu, Qida Hu, Yong Huang, Li Ping, Fu Zhang, Honglin Tang, Tao Wan, Yuan Ping, Bowen Li

Acta Biomaterialia · 2023

DOI: 10.1016/j.actbio.2023.01.050 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Biomaterialia, 2023. Verfasst von Yuan Chen und 10 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China. Hauptthemen laut MEDLINE: Prodrugs, Antineoplastic Agents, Triple Negative Breast Neoplasms, Ferroptosis. Die Arbeit wurde bisher 75-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Natural Science Foundation of Guangdong Province, National Key Research and Development Program of China, National Key Research and Development Program of China Stem Cell and Translational Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chemotherapeutics have been recommended as the standard protocol for inoperable patients with triple-negative breast cancer (TNBC) at advanced stage, yet limited success has been achieved in prolonging survival rates by this monotherapy. A major reason for this failure is the chemo-resistance from traditional apoptotic pathways resulting in poor therapeutic effect. Ferroptosis has become a powerful modality of no-apoptotic cell death, which can effectively evade chemo-resistance in apoptotic pathways. Herein, we propose an active-targeting small-molecular self-assembly nano-prodrug for co-delivery of chemotherapeutics (CPT), Ferrocene (Fc) and GPX4 inhibitor (RSL3) to overcome the chemo-resistance from traditional apoptotic pathways. In this nano-prodrug, the disulfide linkage not only serves as a GSH-responsive trigger, but also exhibits a stable self-assembly behavior that forms nanoparticle. Interestingly, the RSL3 can be loaded during this self-assembly process that forms a three-components nano-prodrug. In tumor environment, the high GSH level can disassemble the nano-prodrug to trigger the release of the parent drug, which can improve the therapeutic effect by synergistic effects of ferroptosis and apoptosis. In different TNBC mice models, the nano-prodrug is encapsulated into RGD-modified phospholipid micelles (DSPE-PEG2000-RGD) and exhibits high anti-tumor and anti-metastasis efficacy, especially in orthotopic models. The application of ferroptosis to assist the enhancement of chemotherapeutics may serve as a promising strategy for TNBC treatment. STATEMENT OF SIGNIFICANCE: Chemotherapeutics have been recommended as the standard of care for palliative and adjuvant treatment in patients with triple-negative breast cancer (TNBC), yet limited success has been achieved in prolonging the overall survival of patients by this monotherapy. A major reason for this failure is the chemo-resistance from traditional apoptotic pathways resulting in poor therapeutic effect. Thus, the co-delivery of the apoptosis and ferroptosis drug may overcome or evade the resistance in chemotherapy-induced apoptotic pathways and provide a promising strategy to combat TNBC. In this work, we developed a small-molecular self-assembly nano-prodrug for co-delivery of chemotherapeutics (CPT), Ferrocene (Fc) and ferroptosis resistance inhibitor (RSL3), which could overcome the chemo-resistance and improve the therapeutic effect by synergistic effects of ferroptosis and apoptosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProdrugsAntineoplastic AgentsTriple Negative Breast NeoplasmsFerroptosisHumansAnimalsMiceMetallocenesCell Line, TumorOligopeptidesFerrous Compounds

Stichwörter der Autor:innen

ChemotherapyCombination therapyFerroptosisSelf-assembly nano-prodrugTriple-negative breast cancer

Substanzen

ProdrugsAntineoplastic AgentsMetallocenesOligopeptidesferroceneFerrous Compounds

Autor:innen und Institutionen

  • College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
  • College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China; Department of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, H…
  • School of Chemistry and Chemical Engineering, Key Laboratory of Clean Energy Materials Chemistry of Guangdong Higher Education Institutes, Lingnan Normal University, Zhanjiang, Guangdong 524048, China. Electronic addres…
  • Department of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou 310003, China.
  • College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China; Liangzhu Laboratory, Zhejiang University Medical Center, 1369 West Wenyi Road, Hangzhou 311121, China.
  • Department of Medical Oncology, Sir Run Run Shaw Hospital, School of Medicine Zhejiang University, Hangzhou 310058, China.

Förderung

  • Natural Science Foundation of Guangdong Province
  • National Key Research and Development Program of China
  • National Key Research and Development Program of China Stem Cell and Translational Research
  • National Natural Science Foundation of China

Zitieren

APA

Chen, Y., Yao, Z., Liu, P., Hu, Q., Huang, Y., Ping, L., Zhang, F., Tang, H., Wan, T., Ping, Y., & Li, B. (2023). A self-assembly nano-prodrug for triple-negative breast cancer combined treatment by ferroptosis therapy and chemotherapy. Acta Biomaterialia. https://doi.org/10.1016/j.actbio.2023.01.050

Vancouver

Chen Y, Yao Z, Liu P, Hu Q, Huang Y, Ping L, et al. A self-assembly nano-prodrug for triple-negative breast cancer combined treatment by ferroptosis therapy and chemotherapy. Acta Biomaterialia. 2023. doi:10.1016/j.actbio.2023.01.050

BibTeX
@article{Chen2023,
  author = {Chen, Yuan and Yao, Zhuo and Liu, Peilian and Hu, Qida and Huang, Yong and Ping, Li and Zhang, Fu and Tang, Honglin and Wan, Tao and Ping, Yuan and Li, Bowen},
  title = {A self-assembly nano-prodrug for triple-negative breast cancer combined treatment by ferroptosis therapy and chemotherapy},
  journal = {Acta Biomaterialia},
  year = {2023},
  doi = {10.1016/j.actbio.2023.01.050}
}
Kostenlos starten →